This trial is testing a new cancer treatment that may improve Event Free Survival rates for women with a certain type of breast cancer.
1 Primary · 4 Secondary · Reporting Duration: 36 Months
Experimental Treatment
80 Total Participants · 1 Treatment Group
Primary Treatment: Nivolumab · No Placebo Group · Phase 2
Age 18+ · Female Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: